Management of latent tuberculosis infection based on t-spot.tb assay in patients with hematological malignancies

Conclusions:INH treatment was generally well tolerated, and serious drug-related side effects were observed infrequently. Although LTBI cannot be demonstrated in patients with HIV(+) HM who are scheduled for chemotherapy, these patients should be closely monitored for the development of active TB infection.Keywords: Hematologic malignancies, Interferon-Gamma Release Assays, Latent tuberculosis
Source: Mediterranean Journal of Hematology and Infectious Diseases - Category: Hematology Authors: Source Type: research